JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

JPMorgan Chase & Co. lifted its stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 4,826,425.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 772,244 shares of the company’s stock after acquiring an additional 772,228 shares during the period. JPMorgan Chase & Co. owned approximately 2.77% of Vistagen Therapeutics worth $2,278,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. R Squared Ltd bought a new stake in Vistagen Therapeutics in the 4th quarter valued at $25,000. Jane Street Group LLC acquired a new stake in shares of Vistagen Therapeutics during the 3rd quarter valued at about $59,000. Virtu Financial LLC increased its stake in Vistagen Therapeutics by 30.5% in the third quarter. Virtu Financial LLC now owns 20,210 shares of the company’s stock valued at $61,000 after acquiring an additional 4,722 shares during the period. HighTower Advisors LLC acquired a new position in Vistagen Therapeutics in the third quarter worth about $64,000. Finally, Prosperity Wealth Management Inc. acquired a new position in Vistagen Therapeutics in the fourth quarter worth about $86,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Vistagen Therapeutics Price Performance

Shares of VTGN stock opened at $2.18 on Thursday. The stock’s fifty day simple moving average is $2.51 and its 200 day simple moving average is $2.73. Vistagen Therapeutics, Inc. has a one year low of $1.90 and a one year high of $4.96. The firm has a market cap of $62.92 million, a price-to-earnings ratio of -1.47 and a beta of 0.56.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. The company had revenue of $230 billion during the quarter, compared to analyst estimates of $0.18 million. On average, research analysts anticipate that Vistagen Therapeutics, Inc. will post -1.77 earnings per share for the current year.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.